Тромбоз, гемостаз и реология. — 2016.

ЛЕЧЕНИЕ АНТИФОСФОЛИПИДНОГО СИНДРОМА: СОВРЕМЕННЫЕ СТАНДАРТЫ

Т. М. Решетняк

ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой», Москва, Россия

В обзоре приведены сведения об этиологии и патогенезе антифосфолипидного синдрома (АФС), генетической предрасположенности к его развитию. Представлены последние международные критерии диагностики AФC и его варианты. Данный синдром в зависимости от локализации тромбоза может поражать несколько систем органов, поэтому проблема AФC в наше время является мультидисциплинарной. Клинические проявления АФС достаточно общие (тромбозы различной локализации), поэтому диагноз может быть верифицирован только при наличии антифосфолипидных антител. Рассмотрена дифференциальная диагностика АФС.

Ключевые слова: тромбофилия — антифосфолипидный синдром — антифосфолипидные антитела — системная красная волчанка.

TREATMENT OF ANTIPHOSPHOLIPID SYNDROME: MODERN STANDARDS

T. M. Reshetnyak

Research Institute of Rheumatology named after V. A. Nasonova, Moscow, Russia

The review presents data about etiology and pathogenesis of antiphospholipid syndrome (APS) and genetic susceptibility to its development. The latest international criteria for diagnostics of AРC and its variants are presented. This syndrome can affect multiple organ systems depending on thrombosis localization; therefore nowadays APS problem is multidisciplinary. Clinical manifestations of APS are rather general (thromboses of different localization); so APS diagnosis can be verified only in presence of antiphospholipid antibodies. The differential diagnostics of APS is discussed.

Key words: thrombophilia — antiphospholipid syndrome — antiphospholipid antibodies — systemic lupus erythematosus.

Литература/References

Антифосфолипидный синдром [Под ред. Е. Л. Насонова]. — М.: Литтера, 2004. — 424 с.

Miyakis S., Lockshin M., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) // J. Thromb. Haemost. — 2006. — Vol. 4. — Р. 295–306.

Решетняк Т. М. Антифосфолипидный синдром // В кн.: Клинические лекции по ревматологии [Под ред. В. В. Бадокина]. — М.: ГЭОТАР-Медиа, 2011. — С. 377–406.

Решетняк Т. М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция) // Научно-практическая ревматология. — 2014. — Т. 52, № 1. — С. 56–71.

Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies [Еds. D. Erkan, S. S. Pierangeli]. — New York: © Springer Science + Business Media, 2012 (doi: 10.1007/978- 1-4614-3194-7_17).

Pengo v. , Tripodi A., Reber G. et al. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardization committee of the international society on thrombosis and haemostasis. Update of the guidelines for lupus anticoagulant detection // J. Thromb. Haemost. — 2009. — Vol. 7, № 10. — P. 1737–1740.

Pengo v. , Ruffatti A., Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome // J. Thromb. Haemost. — 2010. — Vol. 8, № 2. — Р. 237–242.

Pengo v. Classification criteria of thrombotic APS // Proceedings of the 9th Meeting of the European Forum on Antiphospholipid Antibodies. Medycynapraktyczna. Final program and lectures. — Krakow, Poland. — 2013, May 16–18. — Р. 16–17.

Proven A., Bartlett R. P., Moder K. G. et al. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies // Mayo Clin. Proc. — 2004. — Vol. 79, № 4. — Р. 467–475.

Guyatt G. H., Cook D. J., Jaeschke R. et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th еd.) // Chest. — 2008. — Vol. 133 (Suppl 6). — 123S-131S.

Ruiz-Irastorza G., Hunt B. J., Khamashta M. A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies // Arthritis Rheum. — 2007. — Vol. 57, № 8. — Р. 1487–1495.

Ruiz-Irastorza G., Cuadrado M., Ruiz-Arruza I. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies // Lupus. — 2011. — Vol. 20. — Р. 206–218.

Crowther M. A., Ginsberg J. S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome // N. Engl. J. Med. — 2003. — Vol. 349. — Р. 1133–1138.

Finazzi G., Marchioli R., Brancaccio v. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) // J. Thromb. Haemost. — 2005. — Vol. 3. — Р. 848–853.

Torn M., van der Meer F. J., Rosendaal F. R. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism // Arch. Intern. Med. — 2004. — Vol. 164. — Р. 668–673.

Khamashta M. A., Cuadrado M. J., Mujic F. et al. The management of thrombosis in the antiphospholipid-antibody syndrome // N. Engl. J. Med. — 1995. — Vol. 332, № 15. — Р. 993–997.

Levine S. R., Brey R. L., Tilley B. C. et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke // JAMA. — 2004. — Vol. 291. — Р. 576–584.

Tektonidou M. G., Laskari K., Panagiotakos D. B., Moutsopoulos H. M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies // Arthritis Rheum. — 2009. — Vol. 61, № 1. — Р. 29–36.

Erkan D., Yazici Y., Peterson M. G. et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome // Rheumatology (Oxford). — 2002. — Vol. 41. — Р. 924–929.

Ruffatti A., Del Ross T., Ciprian M. et al. Risk factors for a fi rst thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study // Ann. Rheum. Dis. — 2009. — Vol. 68, № 3. — Р. 397–399.

Kaiser R., Cleveland C., Criswell L. A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort // Ann. Rheum. Dis. — 2009. — Vol. 68, № 2. — Р. 238–241.

Pengo v. , Ruffatti A., Legnani C. et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profi le: a multicenter prospective study // Blood. — 2011. — Vol. 118, № 17. — Р. 4714–4718.

Tektonidou M. G., Ioannidis J. P.A, Boki K. A. et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome // Q. J. Med. — 2000. — Vol. 93, № 8. — Р. 523–530.

Giron-Gonzalez J.A., Garcia del Rio E., Rodriguez C. et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals // J. Rheumatol. — 2004. — Vol. 31, № 8. — Р. 1560–1567.

Urbanus R. T., Siegerink B., Roest M. et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study // Lancet Neurol. — 2009. — Vol. 8, № 11. — Р. 998–1005.

Mehdi A. А., Uthman I., Khamashna M. Treatment of antiphospholipid syndrome // Int. J. Clin. Rheumatol. — 2010. — Vol. 5, № 2. — Р. 241–254.

Lassere M., Empson M. Treatment of antiphospholipid syndrome in pregnancy — a systemic review of randomized therapeutic trials // Thromb. Res. — 2004. — Vol. 114, № 5–6. — Р. 419–426.

Tincani A., Lojacono A., Taglietti M. et al. Pregnancy and neonatal outcome in primary antiphospholipid syndrome // Lupus. — 2002. — Vol. 11, № 10. — Р. 649–655.

Ginnakopoulos B., Krilis S. A. Haw I treat the antiphospholipid syndrome // Blood. — 2009. — Vol. 114, № 10. — Р. 2020–2030.

Tutill J. L., Khamashta M. A. Management of antiphospholipid syndrome // J. Autoimmun. — 2009. — Vol. 33, № 2. — Р. 92–98.

Chan A. T., Manson J. E., Feskanich D. et al. Long term aspirin use and mortality in women // Arch. Int. Med. — 2007. — Vol. 167, № 6. — Р. 562–572.

Erkan D., Harrison M. J., Levy R. et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals // Arthritis Rheum. — 2007. — Vol. 56. — Р. 2382–2391.

Bertsias G., Ioannidis J. P.A., Boletis J. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics // Ann. Rheum. Dis. — 2008. — Vol. 67. — Р. 195–205.

Clark P., Walker I. D., Langhorne P. et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage // Blood. — 2010. — Vol. 115, № 21. — Р. 4162–4167.

Empson M., Lasser M., Craig G., Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant // Cochran Database Syst. Rev. (2) — 2005. — Vol. 18, № 2. — CD002859 (doi: 10.1002/14651858.cd002859.pub2).

Noble L. S., Kutteh W. H., Lashey N. et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin // Fertil. Steril. — 2005. — Vol. 83, № 3. — Р. 684–690.

Stephenson M. D., Ballem P. J., Tsang P. et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin // J. Obstet. Gynecol. Can. — 2004. — Vol. 26, № 8. — Р. 729–734.

Locke J. E., Magro C. M., Singer A. L. et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection // Am. J. Transplant. — 2009. — Vol. 9, № 1. — Р. 231–235.

Lonze B. E., Singer A. L., Montgomery R. A. Eculizumab and renal transplantation in a patient with CAPS // N. Engl. J. Med. — 2010. — Vol. 362, № 18. — Р. 1744–1745.

Erkan D., Lockshin M. D. New approaches for managing antiphospholipid syndrome // Nat. Clin. Pract. Rheumatol. — 2009. — Vol. 5, № 3. — Р. 160–170.

Asherson R. A., Cervera R., de Groot P. R. et al. Catastrophic antiphospholipid syndrome: inter- national consensus statement on classification criteria and treatment guidelines // Lupus. — 2003. — Vol. 12, № 7. — Р. 530–534.

Bucciarelli S., Cervera R., Espinosa G. et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors // Autoimmun. Rev. — 2006. — Vol. 6, № 2. — Р. 72–75.

Kitchens C. S., Erkan D., Brandão L. R. et al. Thrombotic storm revisited: preliminary diagnostic criteria suggested by the Thrombotic Storm Study Group // Am. J. Med. — 2011. — Vol. 124, № 4. — Р. 290–296.

Erkan D., Espinosa G., Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms // Autoimmun. Rev. — 2010. — Vol. 10, № 2. — Р. 74–79.

Asherson R. A., Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes («MAPS»): semantic or antisemantic? // Autoimmun. Rev. — 2008. — Vol. 7. — Р. 164–167.

Espinosa G., Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality // Nat. Rev. Rheumatol. — 2010. — Vol. 6, № 5. — Р. 296–300.

Erkan D., Leibowitz E., Berman J., Lockshin M. D. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations // J. Rheumatol. — 2002. — Vol. 29, № 4. — Р. 843–849.

Cervera R., Tektonidou M. G., Espinosa G. et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions // Lupus. — 2011. — Vol. 20. — Р. 165–173.

Cervera R., Bucciarelli S., Plasín M. A. et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the «CAPS Registry» // J. Autoimmun. — 2009. — Vol. 32, № 3–4. — Р. 240–245.

Szczepiorkowski Z. M., Winters J. L., Bandarenko N. et al. Guidelines on the use of therapeutic apheresis in clinical practice — evidence-based approach from the apheresis applications committee of the American Society for Apheresis // J. Clin. Apher. — 2010. — Vol. 25, № 3. — Р. 83–177.

Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome // Autoimmun. Rev. — 2006. — Vol. 6. — Р. 98–103.

Scobe T., Wijetillea S., Khamashta M. A. Management of refractory antiphospholipd syndrome // Autoimmun. Rev. — 2011 (doi:10.1016/j.autrev. 2011.04.030).

Xarelto 10 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of fi rst authorisation/renewal of authorisation: 30/09/08. Date of revision 12/2011. — Available at: www.emc.medicines.org.uk.

Lee C. J., Ansell J. E. Direct thrombin inhibitors // Br. J. Clin. Pharmacol. — 2011. — Vol. 72, № 4. — Р. 581–592.

Gomez-Outes A., Terleira-Fernandez A.I., Calvo-Rojas G. et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systemic review and meta-analysis of subgroups // Thrombosis. — 2013. — Vol. 2013. — Article ID640723 (doi: 10.1155/2013/640723).

Eriksson B. I., Quinlan D. J., Eikelboom J. W. Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism // Annu. Rev. Med. — 2011. — Vol. 62, № 1. — Р. 41–57 (doi: 10.1146/annurevmed-062209-095159).

Bick R. L., Rice J. Long-term outpatients dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety — a preliminary report // Clin. Appl. Thromb. Hemost. — 1999. — Vol. 5 (Suppl 1). — S67-S71.

Montoya R. C., Gajra A. Current status of new anticoagulants in the management of venous thromboembolism // Advances in Hematol. — 2012. — Article ID856341 (doi: 10,1155/2012/856341).

Тромбоз, гемостаз и реология. — 2016. — №1(65). — С. 11-20.

Обзор

ЛЕЧЕНИЕ АНТИФОСФОЛИПИДНОГО СИНДРОМА: СОВРЕМЕННЫЕ СТАНДАРТЫ

TREATMENT OF ANTIPHOSPHOLIPID SYNDROME: MODERN STANDARDS